Evidence map›Paper›PMID 40969300›Full record

ArticleMedComm2025

PACLseq: A Standalone Diagnostic Method for Ph-Like Acute Lymphoblastic Leukemia Using Nanopore Sequencing.

Hang Zhang, Huan Yu, Yanmei Chen, Kai Jiang, Beibei Huo, Jialin Li, Ting Liu, Dan Xie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hang ZhangDepartment of Hematology, Institute of Hematology West China Hospital of Sichuan University Chengdu Sichuan China.ORCID https://orcid.org/0009-0007-3065-4303
Huan YuQitan Technology Ltd. Chengdu Sichuan China.
Yanmei ChenQitan Technology Ltd. Chengdu Sichuan China.
Kai JiangQitan Technology Ltd. Chengdu Sichuan China.
Beibei HuoQitan Technology Ltd. Chengdu Sichuan China.
Jialin LiQitan Technology Ltd. Chengdu Sichuan China.
Ting LiuDepartment of Hematology, Institute of Hematology West China Hospital of Sichuan University Chengdu Sichuan China.
Dan XieLaboratory of Omics Technology and Bioinformatics, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy West China Hospital Sichuan University Chengdu Sichuan China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Timely and accurate detection of Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL)-related fusion gene is essential for treatment decisions. However, due to the complexity of possible gene fusion combinations of Ph-like ALL, current diagnostic workflows face critical limitations: prolonged turnaround (7-14 days), high costs, and deficiency in degraded specimens. In this study, we introduce Partial Anchored Capture and Long-Read Sequencing (PACLseq), a nanopore-sequencing-technology-based approach. We designed a detection panel associated with Ph-like ALL, specifically

Indexed as

gene fusionlong‐read sequencingPhiladelphia chromosome–like acute lymphoblastic leukemiaTarget transcriptome sequencing

Identifiers

PMID40969300
PMCPMC12441304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.